US 11,890,285 B2
Combination therapies
David Briere, San Diego, CA (US); James Gail Christensen, San Diego, CA (US); and Peter Olson, San Diego, CA (US)
Assigned to Mirati Therapeutics, Inc., San Diego, CA (US)
Filed by Mirati Therapeutics, Inc., San Diego, CA (US)
Filed on Sep. 23, 2020, as Appl. No. 17/029,654.
Claims priority of provisional application 62/905,107, filed on Sep. 24, 2019.
Prior Publication US 2021/0085683 A1, Mar. 25, 2021
Int. Cl. A61K 31/519 (2006.01); A61P 35/04 (2006.01); C07K 16/28 (2006.01)
CPC A61K 31/519 (2013.01) [A61P 35/04 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01)] 43 Claims
 
1. A method of treating a KRas G12C-associated cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a PD-1/PD-L1 inhibitor selected from the group consisting of nivolumab, pembrolizumab, cemiplimab, tislelizumab, atezolizumab, avelumab, and durvalumab, and a compound of formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.
 
43. A kit comprising: a) a pharmaceutical composition comprising a PD-1/PD-L1 inhibitor selected from the group consisting of nivolumab, pembrolizumab, cemiplimab, tislelizumab, atezolizumab, avelumab, and durvalumab, and b) a pharmaceutical composition comprising a compound of formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, for treating a KRas G12C cancer in a subject.